The Sapience pipeline is more than a roadmap—it’s a testament to our mission to transform the treatment of hard-to-treat cancers. With SPEARs™ advancing through clinical trials, we are delivering new tomorrows where they’re needed most.
| Program | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
| Lucicebtide (ST101) C/EBPβ | rGBM† | Monotherapy |
|||
| rGBM Window-of-Opportunity Sub-Study †* | Monotherapy |
||||
| ndGBM Window-of-Opportunity Sub-Study * | Combination with SOC |
||||
| ST316 β-catenin | 2L and 3L CRC | Combination with SOC |
|||
| Solid tumors (Wnt pathway) | Monotherapy |
||||
| FraAP | Solid and heme | ||||
| Discovery Programs | Various | Additional programs in hit-to-lead stages |
|||
| Lucicebtide (ST101) C/EBPβ |
| rGBM† |
|
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
Monotherapy |
| rGBM Window-of-Opportunity Sub-Study †* |
|
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
|
Monotherapy |
| ndGBM Window-of-Opportunity Sub-Study * |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
|
Combination with SOC |
| ST316 β-catenin (Wnt pathway) |
| 2L and 3L CRC |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
|
Combination with SOC |
| Solid tumors (Wnt pathway) |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
|
Monotherapy |
| FraAP |
| Solid and heme |
|
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
|
|
| Discovery Programs |
| Various |
|
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
|
Additional programs in hit-to-lead stages |
| Program | Stage | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|
| Program | Stage | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|
†FDA Fast Track Designantion *FDA Orphan Drug Designation